Background: Over the past decade, three new drugs have been approved for the treatment of hereditary amyloid transthyretin (ATTRv) polyneuropathy. The aim of this work was to analyze whether current therapies prolong survival for patients affected by ATTRv amyloidosis. Methods: The study was conducted retrospectively, analyzing the medical records of 105 patients with genetic diagnoses of familial amyloidotic polyneuropathy followed at the two referral centers for the disease in Sicily, Italy. Of these, 71 received disease-modifying therapy, while 34 received only symptomatic treatment or no therapy. Results: The most used treatment in our patient cohort was tafamidis, followed by liver transplantation, patisiran, inotersen, and diflunisal. The median survival was significantly longer for treated vs. untreated patients (12 years vs. 8 years). In the 71 patients who received disease-modifying treatment, the presence of cardiac involvement, weight loss, or autonomic dysfunction at diagnosis was not related to survival. Conversely, patients diagnosed in the early stage of the disease (PND 1) had significantly longer survival than those diagnosed in the late stage (PND 2–4).

Russo M., Gentile L., Di Stefano V., Di Bella G., Minutoli F., Toscano A., et al. (2021). Use of drugs for attrv amyloidosis in the real world: How therapy is changing survival in a non-endemic area. BRAIN SCIENCES, 11(5), 545 [10.3390/brainsci11050545].

Use of drugs for attrv amyloidosis in the real world: How therapy is changing survival in a non-endemic area

Di Stefano V.;Brighina F.;
2021-05-01

Abstract

Background: Over the past decade, three new drugs have been approved for the treatment of hereditary amyloid transthyretin (ATTRv) polyneuropathy. The aim of this work was to analyze whether current therapies prolong survival for patients affected by ATTRv amyloidosis. Methods: The study was conducted retrospectively, analyzing the medical records of 105 patients with genetic diagnoses of familial amyloidotic polyneuropathy followed at the two referral centers for the disease in Sicily, Italy. Of these, 71 received disease-modifying therapy, while 34 received only symptomatic treatment or no therapy. Results: The most used treatment in our patient cohort was tafamidis, followed by liver transplantation, patisiran, inotersen, and diflunisal. The median survival was significantly longer for treated vs. untreated patients (12 years vs. 8 years). In the 71 patients who received disease-modifying treatment, the presence of cardiac involvement, weight loss, or autonomic dysfunction at diagnosis was not related to survival. Conversely, patients diagnosed in the early stage of the disease (PND 1) had significantly longer survival than those diagnosed in the late stage (PND 2–4).
Settore MED/26 - Neurologia
https://www.mdpi.com/2076-3425/11/5/545
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146901/
Russo M., Gentile L., Di Stefano V., Di Bella G., Minutoli F., Toscano A., et al. (2021). Use of drugs for attrv amyloidosis in the real world: How therapy is changing survival in a non-endemic area. BRAIN SCIENCES, 11(5), 545 [10.3390/brainsci11050545].
File in questo prodotto:
File Dimensione Formato  
Use of Drugs for ATTRv Amyloidosis in the Real World How Therapy Is Changing Survival in a Non-Endemic Area.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 1.24 MB
Formato Adobe PDF
1.24 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/520490
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
social impact